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AsBACKGROUND Based on results of the PLATO (Platelet Inhibition and Patient Outcomes) trial comparing ticagrelor
with clopidogrel therapy, the U.S. Food and Drug Administration approved ticagrelor in 2011 for reducing thrombotic
cardiovascular events in patients with acute coronary syndrome (ACS) with the proviso that it be taken with low-dose
aspirin.
OBJECTIVES This study sought to assess the cost and cost effectiveness of ticagrelor therapy relative to clopidogrel in
treating ACS patients from the perspective of the U.S. health care system.
METHODS We estimated within-trial resource use and costs using U.S. low-dose aspirin patients in PLATO (n ¼ 547).
Quality-adjusted life expectancy was estimated using the total PLATO population (n ¼ 18,624), combined with baseline
risk and long-term survival data from an external ACS patient cohort. Study drugs were valued at current costs. Cost
effectiveness was assessed, as was the sensitivity of results to sampling and methodological uncertainties.
RESULTS One year of ticagrelor therapy, relative to that of generic clopidogrel, cost $29,665/quality-adjusted life-year
gained, with 99% of bootstrap estimates falling under a $100,000 willingness-to-pay threshold. Results were robust to
extensive sensitivity analyses, including variations in clopidogrel cost, exclusion of costs in extended years of life, and a
recalibrated estimate of survival reﬂecting a lower underlying mortality risk in the United States.
CONCLUSIONS For PLATO-eligible ACS patients, a U.S. perspective comparison of the current standard of dual
antiplatelet therapy of aspirin with clopidogrel versus aspirin plus ticagrelor showed that the ticagrelor regimen increased
life expectancy at an incremental cost well within accepted benchmarks of good value for money. (A Comparison of
Ticagrelor [AZD6140] and Clopidogrel in Patients With Acute Coronary Syndrome [PLATO]; NCT00391872) (J Am Coll
Cardiol 2015;65:465–76) © 2015 by the American College of Cardiology Foundation.m the *Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina; yDivision of Cardiology,
partment of Medicine, University of Alberta, Edmonton, Alberta, Canada; zDepartment of Medical Sciences, Cardiology and
psala Clinical Research Center, Uppsala University, Uppsala, Sweden; xCenter for Medical Technology Assessment and
partment of Medicine and Health Sciences, Linköping University, Linköping, Sweden; kDepartment of Cardiology and
partment of Medicine and Health Sciences, Linköping University, Linköping, Sweden; {Thrombolysis In Myocardial Infarction
dy Group, Brigham and Women’s Hospital, Boston, Massachusetts; and the #Department of Medicine, Stanford University,
nford, California. This study was supported by AstraZeneca through a research grant to Linköping University, with a sub-
tract to the Duke Clinical Research Institute. The sponsor was asked to provide feedback regarding the U.S. economic substudy
sign, results, and manuscript; however, all ﬁnal decisions regarding the publication and its contents were made independently
sponsor by coauthors. Dr. Cowper has received research support from AstraZeneca, Eli Lilly & Co., Bristol-Myers Squibb/Pﬁzer,
d AGA Medical. Drs. Pan and Kaul have received research support from AstraZeneca and Eli Lilly & Co. Dr. Anstrom has received
earch support from AstraZeneca, Eli Lilly & Co., and Medtronic; consulted for Abbott Vascular, AstraZeneca, Bristol-Myers
uibb, Gilead, Pﬁzer, GlaxoSmithKline, Promedior, and Ikaria; served on data monitoring committees for Forest, Glaxo-
ithKline, Pﬁzer, and Vertex; and holds equity interest in Biscardia. Dr. Wallentin has received research grants from AstraZe-
ca, Merck & Co., Boehringer-Ingelheim, Bristol-Myers Squibb/Pﬁzer, and GlaxoSmithKline; consulted for Abbott, Merck & Co.,
gado Biosciences, Athera Biotechnologies, Boehringer-Ingelheim, AstraZeneca, GlaxoSmithKline, and Bristol-Myers Squibb/
zer; received lecture fees from AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb/Pﬁzer, and GlaxoSmithKline; and
noraria from AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb/Pﬁzer, and GlaxoSmithKline; and travel support from
traZeneca, Bristol-Myers Squibb/Pﬁzer and GlaxoSmithKline. Dr. Janzon has received lecture fees from AstraZeneca and Pﬁzer;
ABBR EV I A T I ON S
AND ACRONYMS
ACS = acute coronary
syndrome(s)
CI = 95% conﬁdence interval
FDA = U.S. Food and Drug
Administration
ICER = incremental
cost-effectiveness ratio
MI = myocardial infarction
PCI = percutaneous coronary
intervention
QALY = quality-adjusted
life-year
STEMI = ST-segment elevation
myocardial infarction
and partici
board parti
has receive
received re
GlaxoSmith
Lipimedix,
Daiichi-San
Zeneca, Bri
in Adverse
Squibb, an
lationships
Listen to th
You can als
Manuscript
Cowper et al. J A C C V O L . 6 5 , N O . 5 , 2 0 1 5
U.S. Economic Analysis of Ticagrelor Therapy F E B R U A R Y 1 0 , 2 0 1 5 : 4 6 5 – 7 6
466D ual antiplatelet therapy (DAPT)with aspirin and an adenosinediphosphate receptor P2Y12 inhibi-
tor is currently recommended for patients
with acute coronary syndrome (ACS) to
reduce risk of myocardial infarction (MI)
and death (1,2). Although clopidogrel is the
drug most commonly used with aspirin for
this purpose, signiﬁcant variability in its an-
tiplatelet effects along with the irrevers-
ibility of its action on the platelet have
prompted searches for an alternative secondSEE PAGE 477antiplatelet agent. The PLATO (Platelet Inhi-
bition and Patient Outcomes) trial reportedthat the combination of ticagrelor, a newer P2Y12 in-
hibitor, and aspirin was superior to clopidogrel plus
aspirin in preventing death and MI (3). Based on these
results, the U.S. Food and Drug Administration (FDA)
approved ticagrelor in 2011 for use in ACS patients in
combination with low-dose aspirin.
Novel therapeutic innovations face intense scru-
tiny regarding not only their safety and clinical
effectiveness but also their value (the balance be-
tween incremental societal costs to provide the care
and its incremental health beneﬁts). Our study’s
objective was to use detailed patient-level clinical
and resource use data collected in PLATO to
evaluate the costs and cost effectiveness of ticagrelor
relative to clopidogrel in treating patients with ACS
from the perspective of the U.S. health care system.
METHODS
PLATO. The PLATO study enrolled 18,624 subjects
with ACS in 43 countries in a randomized, double-
blind clinical trial conducted between October 2006
and February 2009 (3,4). Patients received a loading
dose of study drug, followed by up to 1 year ofpated on the scientiﬁc advisory board for AstraZeneca. Dr. Levin
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received July 2, 2014; revised manuscript received September 2maintenance therapy (ticagrelor, 90 mg twice/day;
clopidogrel, 75 mg daily). Compared with clopidogrel,
ticagrelor signiﬁcantly reduced the primary endpoint
of vascular death, MI, or stroke (9.8% vs. 11.7%;
hazard ratio [HR]: 0.84; p < 0.001), as well as other
secondary endpoints including all-cause death (4.5%
vs. 5.9%; HR: 0.78; p < 0.001), with no increase in
major bleeding (11.6% vs. 11.2%; HR: 1.04; p ¼ 0.43).
Pre-speciﬁed exploratory analyses identiﬁed sig-
niﬁcant interaction between geographic region and
treatment, with a ticagrelor-clopidogrel HR for the
primary endpoint of 1.25 for North America compared
to ratios of 0.80 to 0.86 in other regions (p ¼ 0.05 for
interaction). The North American effect appeared to
be driven by U.S. results (HR: 1.27; p ¼ 0.01 for
interaction) (5). In extensive post hoc analyses, only
maintenance aspirin dose emerged as a potential
effect modiﬁer: with high-dose aspirin, used primar-
ily in the United States, primary event rates were
higher in patients treated with ticagrelor than in
those treated with clopidogrel (6). Although chance
cannot be ruled out as a source of the region-
treatment interaction, FDA approval of ticagrelor
included a boxed warning that maintenance aspirin
doses exceeding 100 mg/day might reduce effective-
ness and should be avoided (7,8).
PLATO U.S. ECONOMIC ANALYSIS. This prospec-
tively designed cost-effectiveness analysis includes a
within-trial comparison of resource use and associ-
ated costs, as well as a long-term cost-effectiveness
analysis. Original plans were to base cost estimates on
U.S. PLATO patients and effectiveness on the overall
trial experience. This split approach was based on the
premise that U.S. resource use patterns would differ
considerably from those in other countries, but
effectiveness of therapy would not be regionally
dependent (9). Consistent with FDA approval, we
modiﬁed our approach to assume ticagrelor would be
prescribed in the context of low-dose aspirin therapy.has received ﬁnancial support for lectures, advisory
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467Because <40% of U.S. patients received low-dose
aspirin and costs based on total U.S. sample might
not reﬂect the FDA-approved therapy, we estimated
within-trial costs using the low-dose aspirin U.S.
cohort. As planned, we based effectiveness on the
overall trial, in which low-dose aspirin therapy was
predominant. Although U.S. patients had higher
baseline risk than those enrolled elsewhere, use of
overall effectiveness in the U.S. analysis was sup-
ported by the near absence of risk factor-treatment
interactions (2 of 31 risk factors) (3). Because mortal-
ity rates with clopidogrel therapy were lower in
the U.S. subset than in the rest of the PLATO popu-
lation, we also developed recalibrated models to
address the possibility of reduced absolute beneﬁts in
the United States. Inputs to the cost-effectiveness
analysis are described below and summarized in
Online Table 1.
WITHIN-TRIAL RESOURCE USE. Resource use data
for major components of health care were collected
on the case report form and included dates of
admission and discharge for all hospitalizations; days
in intensive care (follow-up hospitalizations only);
and details regarding major procedures, therapies,
and diagnostic tests, including percutaneous coro-
nary revascularization (PCI), cardiac surgeries, coro-
nary angiography, noninvasive cardiac imaging, and
transfusions. Intensity of care during the index hos-
pitalization was not recorded; we assumed patients
were treated in the coronary care unit (CCU) for the
ﬁrst 2 days of their stay and in the cardiology ward
thereafter. For follow-up hospitalizations, procedure
and diagnosis information was used to assign the
intensive care days, as recorded in the case report
form, to speciﬁc hospital units (thoracic intensive
care, CCU, or intensive care unit).
ESTIMATION OF COSTS. Duration of treatment with
study drug was obtained from the case report form.
Study drug costs were based on the National Average
Drug Acquisition Cost (ticagrelor ¼ $7.88/day;
clopidogrel ¼ $0.11/day) (10). The analysis excluded
concomitant drug costs because days on concomitant
medications were similar between treatment groups.
Because cost data were not collected in PLATO,
external cost weights were required to value health
care services collected on the case report form. We
developed cost weights for hospital services using
detailed, patient-level cost accounting data for pa-
tients with coronary disease hospitalized at Duke
University Medical Center from 2006 through 2008.
A generalized linear model for hospitalization cost was
speciﬁed with an identity link and a gamma distri-
bution function (11). Independent variables includedmajor resources collected in PLATO, along with vari-
ables to capture major procedures not collected in the
trial. Unit costs are presented in Online Table 2.
The cost of physician services for resources tracked
in PLATO, including daily hospital care, procedures,
and tests were based on the Medicare fee schedule
(12). Each identiﬁed service was mapped to the cor-
responding current procedural terminology code, and
North Carolina rates were applied.
Within-trial patient-level costs were calculated by
applying cost weights to resources consumed during
the study period by U.S. low-dose patients. Produc-
tivity losses and informal care costs were not
collected in PLATO and were excluded. Costs were
updated to 2013 using the general medical and sur-
gical hospital component of the producer price index
(13). Because PLATO was an event-driven trial, indi-
vidual follow-up times varied. To account for differ-
ential follow-up, 12-month costs were estimated
using inverse probability weighting methods that
account for administrative censoring (14).
We conservatively assumed that nonfatal events
prevented by ticagrelor would not reduce cost or
mortality beyond trial follow-up. Because there are
no known factors that would differentially increase
the cost of care after ticagrelor discontinuation,
treatment-related costs beyond trial follow-up were
limited to background costs in years of life gained
with therapy. An estimate of average annual health
care expenditures, including inpatient care, outpa-
tient services, and medications, was developed using
2008 Medical Expenditure Panel Survey data for
patients reporting coronary heart disease, angina, or
MI (15).
ESTIMATING SURVIVAL AND HEALTH-RELATED
QUALITY OF LIFE. Projections of survival following
an intervention require assumptions regarding long-
term treatment beneﬁts. For our base case, we
assumed that ticagrelor therapy was discontinued
after 1 year with no additional reduction in mortality
risk after cessation of therapy. To model life expec-
tancy, we used a 2-stage approach that relied on
within-trial experience for the 1-year treatment phase
and used external data to extrapolate beyond treat-
ment (16). The external dataset selected for extrapo-
lation was the U.S. cohort from PURSUIT (Platelet
Glycoprotein IIb/IIIa in Unstable Angina: Receptor
Suppression Using Integrilin Therapy) (17), an inter-
national trial that enrolled non–ST-segment elevation
ACS patients. Vital status at 10-year follow-up was
ascertained for 79% of U.S. patients (n ¼ 2,773) by
using the National Death Index.
Survival through 1 year of treatment was estimated
using a conventional time-based Cox proportional
TABLE 1 Baseline Characteristics for the U.S. Cohort by Maintenance Aspirin Dose and Treatment*
U.S. Cohort U.S. Low-Dose Cohort
High-Dose Aspirin
(n ¼ 866)
Low-Dose Aspirin
(n ¼ 547) p Value†
Ticagrelor Group
(n ¼ 284)
Clopidogrel Group
(n ¼ 263) p Value‡
Age, yrs 60 (52–69) 62 (54–71) <0.001 62 (55–70) 63 (54–72) 0.35
Female 26.1 32.9 0.006 33.1 32.7 0.92
Body mass index, kg/m2 29 (26–33) 29 (26–34) 0.53 29 (26–34) 29 (26–34) 0.97
Race 0.71 0.63
White 89.2 89.6 91.2 87.8
Black 10.1 9.1 7.8 10.7
Asian 0.5 0.9 0.7 1.1
Other 0.4 0.4 0.4 0.4
Baseline clinical history
Prior MI 27.6 27.1 0.81 27.5 26.6 0.82
Prior PCI 30.3 28.0 0.35 28.2 27.8 0.91
Prior CABG 15.7 18.3 0.21 19.4 17.1 0.50
CHF 6.4 9.3 0.04 7.8 11.0 0.19
Hypertension 68.0 75.3 0.003 74.7 76.1 0.70
Dyslipidemia 69.3 65.5 0.13 65.9 65.0 0.84
Nonhemorrhagic stroke 3.6 3.3 0.77 3.5 3.0 0.75
PAD 8.4 10.4 0.21 10.6 10.3 0.91
Chronic renal disease 5.1 7.1 0.11 7.4 6.8 0.80
Diabetes 33.1 34.0 0.72 34.9 33.1 0.66
History of dyspnea 26.1 24.3 0.45 23.9 24.7 0.83
COPD 13.1 11.9 0.52 12.0 11.8 0.95
Smoking 0.20 0.61
Nonsmoker 28.9 30.4 29.6 31.2
Ex-smoker 32.8 36.0 34.9 37.3
Habitual smoker 38.3 33.6 35.6 31.6
Index ACS diagnosis 0.02 0.78
STEMI 17.5 13.0 13.7 12.2
NSTEMI 65.4 70.2 68.3 72.2
Unstable angina 9.3 11.3 12.3 10.3
Other/missing 7.9 5.5 5.6 5.3
Procedures during study
Planned invasive treatment 95.8 90.1 <0.001 90.5 89.7 0.77
PCI 69.3 62.5 0.009 63.0 62.0 0.80
CABG 14.2 12.4 0.34 12.0 12.9 0.73
Study drug
Time from event to
study drug, h
16.5 (8.3–23.0) 17.1 (9.3–22.9) 0.36 16.6 (8.3–22.1) 17.6 (10.6–23.2) 0.13
Time taking drug, days 265 (51–363) 303 (182–366) <0.001 298 (177–366) 329 (189–365) 0.57
Compliant 61.2 62.7 0.57 62.7 62.7 0.99
Premature discontinuation 32.9 25.8 0.004 27.8 23.6 0.26
Values are median (25th-75th percentiles) or %. *Hours from event to study drug and days taking the drug regimen in the high-dose U.S. group have 7% missing data; all other
variables have <1% missing data. †High-dose versus low-dose aspirin. ‡Ticagrelor group versus clopidogrel group.
ACS ¼ acute coronary syndrome; CABG ¼ coronary artery bypass graft surgery; CHF ¼ congestive heart failure; COPD ¼ chronic obstructive pulmonary disease;
MI ¼ myocardial infarction; NSTEMI ¼ non-ST-segment elevation myocardial infarction; PAD ¼ peripheral artery disease; PCI ¼ percutaneous coronary intervention;
STEMI ¼ ST-segment elevation myocardial infarction.
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468hazards model with adjustment for baseline covar-
iates and stratiﬁcation by treatment. Survival
beyond 1 year was estimated using an age-based
survival model, which treats the hazard of death as
a function of age rather than time to take full
advantage of the patient years of follow-up (21,136
patient years). The time-based and age-based modelswere combined to estimate patient-speciﬁc lifetime
survival curves. Life expectancies, calculated as the
area under individual survival curves, were averaged
to obtain a mean predicated life expectancy by
treatment.
In PLATO, observed mortality in the clopidogrel
arm was lower in the U.S. subset than in the rest of
TABLE 2 Within-Trial Use of Resources for U.S. Low-Dose Cohort*
Parameter
Ticagrelor Group
(n ¼ 284)
Clopidogrel Group
(n ¼ 263) Difference† p Value
Index
Days‡ 3.95  3.28 (2,3,4) 4.10  3.52 (2,3,4) 0.15 0.59
PCI 60.6% 59.7% 0.9% 0.84
CABG 10.6% 11.0% 0.4% 0.86
Follow-up
Hospitalizations 0.59  0.99 (0,0,1) 0.60  0.95 (0,0,1) 0.01 0.47
Ward days 2.26  4.88 (0,0,2) 2.69  6.82 (0,0,3) 0.43 0.43
Intensive care§ 0.34  1.49 (0,0,0) 0.34  1.59 (0,0,0) 0 0.80
CCU days 0.19  0.84 (0,0,0) 0.22  1.39 (0,0,0) 0.03 0.98
ICU days 0.15  1.04 (0,0,0) 0.12  0.66 (0,0,0) þ0.03 0.99
PCI 12.7% 10.7% 2.0% 0.46
CABG 1.4% 1.9% 0.5% 0.65
Values are mean  SD, %, or mean  SD (25th, 50th, 75th percentiles). *Observed data in PLATO (6 to 12 months
of follow-up). †Ticagrelor group minus clopidogrel group. ‡For costing purposes, the ﬁrst 2 days were assumed
to be in the CCU, with the remainder in the cardiology ward. §Intensive care days were assigned to CCU or
ICU based on ﬁnal discharge diagnoses and procedures.
CCU ¼ coronary care unit; ICU ¼ intensive care unit; other abbreviations as shown in Table 1.
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469the trial population (3.6% vs. 6.1%, respectively) (5).
Although other international studies of ACS pop-
ulations have not found U.S. mortality rates to be
40% lower than elsewhere (18,19), effectiveness es-
timates based on the overall trial might exaggerate
the underlying U.S. mortality risk, thereby inﬂating
predicted absolute gains in survival associated with
ticagrelor treatment. Therefore, we performed an
alternative set of analyses in which underlying
mortality risk was recalibrated to reﬂect the lower
observed rate of death among U.S. clopidogrel
patients.
The EuroQol ﬁve dimensional health state
classiﬁcation instrument (EQ-5D) was collected in
PLATO as a measure of health-related quality of life
(QOL) at baseline and regular follow-up intervals in
countries with ofﬁcial EQ-5D translations (92% of
enrolled patients). No differences between treat-
ments in EQ-5D scores were observed (20). We esti-
mated an age-dependent QOL adjustment factor for
patients living with ACS using the last complete EQ-
5D assessment for each patient, valued with U.S.
preference weights (21,22).
STATISTICAL ANALYSES. Baseline characteristics of
the U.S. low-dose aspirin maintenance cohort were
compared with those of the high-dose cohort to
determine whether, with the exception of aspirin
dose, the low-dose subset represented U.S. patients.
Within-trial resource use (index and follow-up)
was summarized using descriptive statistics and
compared by treatment group using Pearson chi-
square test for proportions and Mann-Whitney U
test for continuous variables. Cumulative 1-year
costs, estimated using inverse probability weighting
methods, were compared between treatments using
the normal approximation, with standard errors
estimated using a bootstrap approach (described
below). Because the distribution of within-trial costs
in the U.S. low-dose cohort had a positive skew with a
few extreme outliers whose reproducibility could not
be determined, outliers exceeding the 99th percentile
were replaced with the 99th percentile value (Win-
sorized) in primary analyses.
Incremental cost-effectiveness ratios (ICERs) were
calculated as the between group difference in mean
lifetime costs divided by the between group differ-
ence in mean quality-adjusted life expectancy. In
light of considerable uncertainty surrounding the
small cost offset favoring ticagrelor found in the U.S.
low-dose subset, we excluded within-trial health care
costs from the base case cost-effectiveness analysis.
The base case, estimated using the overall sample,
included a generic clopidogrel cost of $0.11 per day;health care costs in years of life gained with tica-
grelor; persistence beyond trial follow-up of within-
trial gains in survival; and a discount rate of 3% for
costs and survival. Sensitivity analyses assessed the
effect of methodological assumptions on results.
Assuming no within-trial cost offset, we examined
the effects of varying average clopidogrel cost ($0/
day to $6/day), excluding costs in years of life gained,
removing the QOL adjustment, varying the discount
rate (0% and 6%), and restricting the time horizon
over which survival beneﬁts could accrue (within-
trial and 5 years). Cost effectiveness in subgroups of
interest was also explored. We then incorporated
within-trial costs using the U.S. low-dose cohort and
assessed their effect on cost effectiveness. Scenarios
included variations in the externally derived cost
weights (50% and 150% of base values) and inclusion
of all observed cost data (without Winsorizing out-
liers). Combinations of these sensitivity analyses
were examined to assess the effect of changing
several key parameters simultaneously. All analyses
were repeated after recalibrating survival using
observed within-trial experience of the U.S. clopi-
dogrel cohort.
For each scenario, sampling uncertainty was char-
acterized using nonparametric bootstrap techniques,
resampling 1,000 times with replacement. In sce-
narios using U.S. low-dose costs, the joint distribu-
tion of costs and effects was preserved to the extent
possible by stratifying bootstrap sampling by region
(U.S. low-dose vs. rest of world) and then combining
the 2 subsamples to create an overall sample for
each bootstrap repetition. Conﬁdence intervals were
calculated for differences in cost and effects using the
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TABLE 3 Cumulative 1-Year Within-Trial Costs for U.S. Low-Dose Cohort*
Cost Ticagrelor Group (n ¼ 284) Clopidogrel Group (n ¼ 263) Difference (95% CI)† p Value
Medical costs (observed) 29,223 (26,655–31,790) 30,716 (27,155–34,277) 1,493 (5,884 to 2,897) 0.50
Medical costs (Winsorized) 29,191 (26,648–31,735) 29,907 (26,999–32,815) 716 (4,579 to 3,147) 0.72
Study drug 2,204 (2,072–2,336) 32 (30–34) 2,172 (2,040 to 2,304) <0.001
Total (Winsorized) 31,395 (28,848–33,942) 29,939 (27,031–32,847) 1456 (2410 to 5,322) 0.46
Values are mean (95% conﬁdence interval). *One-year estimates were derived using inverse probability weighting. †Ticagrelor group minus clopidogrel group.
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470normal approximation, with standard errors esti-
mated from the bootstrap. Incremental cost effec-
tiveness was examined graphically on the
cost-effectiveness plane and summarized using cost-
effectiveness acceptability curves (23). All costs
were expressed in 2013 dollars. Analyses were per-
formed using SAS version 9.3 software (SAS Institute,
Cary, North Carolina).
RESULTS
BASELINE CHARACTERISTICS. A comparison of
baseline characteristics of U.S. and non-U.S. patients
enrolled in PLATO has been published (5). Compared
to the non-U.S. cohort, U.S. patients had a less
favorable risk proﬁle, with higher rates of diabetesumulative Within-Trial Costs
Clopidogrel
Ticagrelor
95% Confidence Interval - Clopidogrel
95% Confidence Interval - Ticagrelor
3 6
Month of Follow-up
9 12
rug and Winsorized health care costs, treatment groups are compared
atment for the U.S. low-dose aspirin cohort. Brackets are conﬁdence(33% vs. 24%, respectively), chronic obstructive pul-
monary disease (13% vs. 5%, respectively), previous
MI (27% vs. 20%, respectively), dyslipidemia (68%
vs. 45%, respectively), non–ST-segment elevation
myocardial infarction (NSTEMI) presentation (67%
vs. 41%, respectively), and previous revascularization
(29% vs. 12% PCI, respectively; 17% vs. 5% bypass
surgery, respectively; all p < 0.001). However, within
the U.S. cohort, characteristics of patients receiving
low-dose aspirin were very similar to those receiving
high-dose aspirin (Table 1). Minor differences
included a higher proportion of females and higher
rates of NSTEMI presentation, congestive heart fail-
ure, and hypertension in low-dose aspirin patients.
Within the low-dose U.S. cohort, baseline risk was
balanced between treatments (Table 1).
WITHIN-TRIAL CONSUMPTION AND COST OF MEDICAL
RESOURCES. Resource use during the index hos-
pitalization in the ticagrelor arm was similar to that in
the clopidogrel arm, with an average length of stay of
3.95 versus 4.10 days, respectively, and w70% of
patients undergoing revascularization (Table 2). The
average number of readmissions did not differ by
treatment (0.59 vs. 0.60, respectively). Although the
number of nonintensive care days during follow-up
was slightly lower in the ticagrelor group (mean ¼
2.26 vs. 2.69, respectively; p ¼ 0.43), days in intensive
care and revascularizations were similar (Table 2)
(detailed resource use counts are shown in Online
Table 2). The small differences in length of stay
led to slightly lower but statistically similar cumu-
lative costs at 1 year (Table 3) (Winsorized
difference ¼ $716, 95% conﬁdence interval [CI]:
$4,579 to $3,147; p ¼ 0.72). When antiplatelet ther-
apy costs were included, cumulative within-trial
costs were slightly higher with ticagrelor ($31,395 vs.
$29,939, respectively; p ¼ 0.46) (Figure 1).
LIFE EXPECTANCY AND QOL. The lifetime extrapo-
lation model yielded undiscounted life expectancy
estimates of 16.60 (95% CI: 16.47 to 16.73) and 16.38
(95% CI: 16.25 to 16.52) years in the ticagrelor and
clopidogrel groups, respectively. After discounting
FIGURE 3 Cost-Effectiveness Acceptability Curves Excluding Within-Trial Cost Offset
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FIGURE 2 Distribution of Lifetime Incremental Cost and Effectiveness: Base Case
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471at 3% annually, average life expectancy with tica-
grelor exceeded that with clopidogrel by 0.16 years
(95% CI: 0.05 to 0.27; p ¼ 0.004; ticagrelor ¼ 12.06,
clopidogrel ¼ 11.90). QOL as measured by patients’
last EQ-5D score averaged 0.886 (n ¼ 15,713). EQ-5D
scores decreased with age (mean values by age
group were <45 ¼ 0.930; 45 to 54 years ¼ 0.907; 55 to
64 years ¼ 0.900; 65 to 75 years ¼ 0.876; 75 to
84 years ¼ 0.836; and $85 years ¼ 0.799). Adjusting
survival for QOL reduced gains to 0.137 years (95%
CI: 0.038 to 0.236; p ¼ 0.007; ticagrelor ¼ 10.44,
clopidogrel ¼ 10.30) (Online Table 3).
LIFETIME COSTS AND COST EFFECTIVENESS. Based
on 2008 Medical Expenditure Panel Survey data,
total annual medical expenditures for patients with
coronary disease (inpatient, outpatient, and medi-
cations) averaged $12,376. Projected lifetime costs
(excluding study drug) averaged $1,863 more with
ticagrelor than clopidogrel ($137,279 vs. $135,417;
p ¼ 0.006). Incorporating the incremental cost of
study drug ($2,195) yielded a total incremental
lifetime cost of $4,058 for ticagrelor compared to
clopidogrel.
Under base case assumptions, ticagrelor’s addi-
tional cost, relative to generic clopidogrel, was
$29,665/quality-adjusted year of life (QALY) gained
with a 98.7% likelihood of being cost effective at a
willingness-to-pay threshold of $100,000 (Online
Table 3). Variation in life expectancy and related
chronic medical costs, along with minor variation in
days taking study drug, created some uncertainty
around this estimate (Figure 2). Cost effectiveness of
ticagrelor improved slightly when the QOL adjust-
ment was removed (ICER ¼ $25,457/life-year gained)
and when the annual cost of medical care beyond the
trial was excluded (ICER ¼ $16,050/QALY gained)
(Figure 3). Increasing the average cost of clopidogrel
toward the proprietary cost ($6/day) improved the
cost-effectiveness proﬁle of ticagrelor, with the ICER
falling to $17,288 and a 99% likelihood of meeting a
$100,000 threshold (Online Table 3). Varying the
discount rate within accepted ranges (0% and 6%)
caused minimal changes to cost effectiveness
(Figure 3). When the lifetime horizon was limited to 5
years, the ICER increased to $58,049 but met a
$100,000 threshold with near certainty (Online
Table 3). Only in the most extreme scenario, which
assumed that reductions in mortality observed in
PLATO did not produce additional life expectancy
beyond 1 year, was ticagrelor unlikely to be cost
effective (ICER ¼ $268,881/QALY gained). Cost
effectiveness was reasonably consistent in subgroups
examined, in keeping with the absence of in-
teractions between treatment and baseline risk(Table 4) (3). ICERs varied with differences among
subgroups in absolute within-trial mortality risk and
life expectancy projections.
Incorporating within-trial costs in the analysis
reduced incremental cost to $3,319 but increased
uncertainty considerably (Figure 4), with little
net effect on the likelihood of meeting a $100,000
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TABLE 4 Lifetime Cost and Cost Effectiveness in Overall Cohort by Subgroup*
Subgroup
Sample Size QALYs†
Difference in QALYs (95% CI)‡
Cost†
Difference in Cost (95% CI)‡ ICER
ICER
<$100,000§T C T C T C
Diabetes
Yes 2,326 2,336 8.2 8.1 0.11 (0.06 to 0.27) $108,007 $104,587 $3,420 ($1,181 to $5,659) $32,145 83.5
No 6,999 6,952 11.2 11.0 0.14 (0.03 to 0.25) $149,948 $145,821 $4,127 ($2,690 to $5,563) $30,189 97.3
ACS type
STEMI 3,496 3,530 11.5 11.4 0.09 (0.07 to 0.24) $153,558 $150,019 $3,539 ($1,522 to $5,556) $40,816 79.2
NSTEMI 4,005 3,950 9.8 9.6 0.17 (0.02 to 0.31) $130,572 $126,187 $4,385 ($2,427 to $6,342) $26,245 97.3
Treatment plan
Invasive 6,732 6,676 10.9 10.7 0.16 (0.05 to 0.27) $145,261 $140,947 $4,314 ($2,826 to $5,802) $27,331 98.7
Medical 2,601 2,615 9.3 9.3 0.07 (0.12 to 0.25) $124,612 $121,411 $3,201 ($734 to $5,668) $47,068 67.9
Age, yrs
<65 5,311 5,334 12.5 12.4 0.09 (0.01 to 0.18) $166,345 $162,808 $3,537 ($2,333 to $4,741) $37,236 92.8
6574 2,626 2,475 8.7 8.5 0.18 (0.08 to 0.28) $117,849 $113,221 $4,628 ($3,117 to $6,140) $25,721 99.8
$75 1,396 1,482 5.7 5.6 0.15 (0.04 to 0.27) $78,139 $74,096 $4,043 ($2,297 to $5,789) $26,274 98.9
*Subgroup analyses mirror the base case and exclude within-trial health care costs. †Mean values. ‡Mean differences of ticagrelor group minus clopidogrel group. §Percentage of 1,000 bootstrap samples.
C ¼ clopidogrel; ICER ¼ incremental cost-effectiveness ratio; QALY ¼ quality-adjusted life year; T ¼ ticagrelor; other abbreviations as in Table 1.
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472threshold (Figure 5). Similarly, increasing (or
decreasing) unit costs and associated cost offset
reduced (or increased) both the ICER estimate and its
precision, leaving the likelihood of satisfying a
$100,000 threshold virtually unchanged (Figure 5).
When Winsorized values were replaced by observed
costs, the within-trial offset increased 50% to $1,494,
reducing incremental cost to $2,541 and impro-
ving the ICER to $18,576/QALY gained, with a 98%tion of Lifetime Incremental Cost and Effectiveness, Including
fset
0.3 -0.2
Difference in Discounted Quality-Adjusted Life Years
-0.1 0.1
$100,000 / quality-adjusted
year of life gained
0.2 0.3 0.40
ial health care costs are added to the base scenario. Point estimate is
blue circle; differences ¼ ticagrelor minus clopidogrel.likelihood of satisfying a willingness-to-pay threshold
of $100,000 (Figure 5).
To address concerns that the clinical effect
achievable in the United States may be overestimated
by the overall PLATO result, we repeated our analysis
after recalibrating survival projections to reﬂect the
lower mortality observed in the U.S. clopidogrel
group. In that scenario, the incremental beneﬁt fell
from 0.14 to 0.10 QALYs, resulting in an ICER of
$36,507 and a 92% likelihood of meeting a $100,000
threshold (Figure 6). When the within-trial cost offset
was incorporated, or costs in additional years of life
were excluded, the estimated ICER improved
considerably, although the likelihood of satisfying a
willingness-to-pay threshold of $100,000 fell with
inclusion of the cost offset due to the underlying
uncertainty (Figure 6). Results of all sensitivity ana-
lyses are presented in Online Table 3 and summarized
in the Central Illustration.
DISCUSSION
Our analysis suggests that relative to the estab-
lished DAPT regimen of clopidogrel plus aspirin,
ticagrelor plus low-dose aspirin increases life ex-
pectancy in ACS patients at an additional cost
that compares favorably with accepted benchmarks
for U.S. medical interventions. These ﬁndings rest
entirely on the mortality reduction observed in
PLATO. In keeping with the FDA approval of tica-
grelor, we have assumed that the relative reduction
in mortality risk observed in PLATO can be obtained
in the United States in the context of low-dose
aspirin therapy. Rejection of this premise (and
FIGURE 6 Cost-Effectiveness Acceptability Curves: Recalibrated Effectiveness
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FIGURE 5 Cost-Effectiveness Acceptability Curves Including Within-Trial Cost Offset
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473acceptance of the observed lack of treatment effect
in the small U.S. subgroup) would render the issue
of cost effectiveness moot.
Our primary results are based on a conservative
scenario that included: 1) no mortality beneﬁt from
reductions in nonfatal MI beyond that observed in
PLATO; 2) no reduction in health care costs during
treatment with ticagrelor; 3) a comprehensive esti-
mate of costs in years of life gained with ticagrelor;
and 4) use of generic clopidogrel only. Relaxing
these assumptions improved the value of ticagrelor.
Ticagrelor therapy remained cost effective after
recalibrating the underlying mortality risk to reﬂect
the U.S. PLATO clopidogrel cohort’s experience.
Only when the time horizon over which ben-
eﬁts and costs accrued was limited to the short
term did the cost effectiveness of ticagrelor appear
unlikely.
Economic analyses of PLATO data from a European
perspective have estimated cost-effectiveness ratios
for ticagrelor (versus clopidogrel) in the range of
$4,000 to $6,000/QALY gained (24,25). These more
favorable ﬁndings stem primarily from the lower
incremental cost of ticagrelor in Europe (30% of U.S.
costs), substantially lower estimates of medical costs
after trial follow-up, and the small but signiﬁcant
reduction in intensive care days observed with
ticagrelor among non-U.S. PLATO patients. A recent
literature-based decision analysis from a U.S.
perspective of DAPT after PCI in ACS patients esti-
mated an ICER for ticagrelor (relative to clopidogrel)
of $40,270/QALY gained (26).
An alternative thienopyridine, prasugrel, was re-
ported to be a dominant strategy relative to clopi-
dogrel in an ACS PCI population, with a cost offset
of $221 and incremental life expectancy of 0.102
years (27). However, when availability of generic
clopidogrel was assumed ($1/day) and costs in
extended years of life included, the ICER rose
to $14,655/life-year gained (2005 dollars). In con-
trast to our study, these estimates were predicated
on extrapolating survival beneﬁts from nonfatal
events avoided during treatment. However, results
of the 2 studies are not directly comparable given
differences in the target population and higher
underlying mortality rates in PLATO (5.9% vs. 3.2%
in the clopidogrel arm) (28).
Although our analyses showed ticagrelor to be a
cost-effective treatment relative to clopidogrel in
the U.S. setting (Central Illustration), the ﬁnancial
impact on pharmacy budgets of widespread adoption
of the new therapy at the current price could still
be substantial. Furthermore, in the current frag-
mented, multi-payer environment, those funding themedication may differ from those who recoup any
potential cost offsets.
STUDY LIMITATIONS. First, lower U.S. enrollment
than anticipated, together with an unexpected
region-treatment interaction and consequent FDA
recommendation to use ticagrelor only with low-dose
aspirin, produced a small sample size with which to
estimate U.S. resource use and costs. Given the
CENTRAL ILLUSTRATION U.S. Economic Analysis of Ticagrelor Therapy in Patients With
Acute Coronary Syndrome
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The incremental cost-effectiveness ratio (ICER) and probability of meeting willingness-to-pay thresholds of $50,000 and $100,000/
quality-adjusted life-year are shown for the base case and for key alternative scenarios. Scenarios are ordered by ICER. Cost offset refers to
within-trial costs.
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474signiﬁcant differences observed in resource use be-
tween the United States and elsewhere (hospital days
of 6.8 vs. 12.7, respectively; overall trial resource use
is shown in Online Table 4), we felt that dealing with
sampling uncertainty was preferable to estimating
cost with resource use inconsistent with U.S. practice
patterns. Second, use of a trial subset to estimate
incremental cost in analyses that incorporated
within-trial costs limited the extent to which the joint
distribution between costs and effects was reﬂected
in the cost-effectiveness results. Third, to the extent
that the underlying U.S. mortality rate is less than
that in the PLATO clopidogrel cohort, absolute
beneﬁts attainable in the United States may have
been overestimated. However, cost effectiveness was
maintained when underlying mortality risk was
recalibrated. Fourth, because empirical cost data
were not collected in PLATO, an analysis from the
U.S. perspective required that health services be
valued with externally derived unit costs. Althoughunit cost estimates were based on experience at one
institution, they were estimated using actual cost
data (not reimbursement or charges) and were inter-
nally consistent. Overall conclusions were unchanged
with wide variations in unit costs. Fifth, evaluating
an intervention’s cost effectiveness requires extrap-
olation of survival beyond trial follow-up. Although
our survival models were developed using an
ACS dataset that excluded those presenting with
STEMI, patients with a history of MI were included,
resulting in a broad mix of ACS patients upon which
to base long-term projections. Our estimates of life
expectancy are similar to those developed inde-
pendently for a European economic evaluation of
ticagrelor (24). Sixth, as with most trial-based eco-
nomic evaluations of new therapies, little informa-
tion was available regarding long-term efﬁcacy and
cost. We assumed therapy would be discontinued
at 12 months, but that treatment-related survival
advantages achieved during the ﬁrst year would
PERSPECTIVES
COMPETENCY IN SYSTEMS-BASED PRACTICE: In patients
hospitalized with ACS, treatment with ticagrelor plus low-
dose aspirin for 1 year, instead of clopidogrel and aspirin,
improved life expectancy at an additional cost that falls
within accepted benchmarks for value in the U.S. health
care system.
TRANSLATIONAL OUTLOOK: Collection of economic data as
part of long-term follow-up of ACS patients managed with dual
antiplatelet therapy in community practice in the United States
could enhance understanding of the relative value of alternative
treatment options.
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475persist. Only when the time horizon was limited to
the short term was the cost effectiveness of tica-
grelor jeopardized. Seventh, analyses of cost effec-
tiveness in patient subgroups were not designed a
priori and should be considered exploratory.
Finally, while prasugrel is now a relevant treatment
alternative for ACS patients, it was beyond this
paper’s scope to assess ticagrelor’s cost effective-
ness relative to this new therapeutic option.
CONCLUSIONS
Ticagrelor therapy for PLATO-eligible ACS patients, in
combination with low-dose aspirin, is economically
attractive relative to clopidogrel from the perspective
of the U.S. health care system under a wide range of
assumptions regarding health care costs and mortality
beneﬁt.
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